Recently, Kim et al. [54] have demonstrated that pre-BCR+ ALL cell lines are exclusively and exquisitely sensitive to Ibrutinib treatment and that in mouse xenograft models of pre-BCR+ ALL, mice who received Ibrutinib had significantly enhanced survival. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.